Trial Profile
Mulpleta Tablets 3mg drug use-results survey
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Lusutrombopag (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shionogi
- 29 Jul 2022 Results of a pooled analysis (JapicCTI-163289, NCT02389621 and JapicCTI-163432 studies) assessing the pharmacokinetics, efficacy, and safety of lusutrombopag in patients with Child-Pugh class C chronic liver disease published in the Advances in Therapy
- 01 Oct 2019 Results (data cut off: Sep 2018) published in the Hepatology Research
- 16 Nov 2016 New trial record